Missed diagnostic testing has negative impact on lung cancer treatment
the ONA take:
A team of researchers from the Baptist Cancer Center and the University of Memphis, Tennessee, sought to identify the impact of factors associated with care delivery on prognosis for patients with lung cancer.
Their results show that only 1 in 10 patients with lung cancer underwent the recommended combination of diagnostic tests before surgery. In addition, patients waited 1.5 to 6 months to undergo surgery after suspicions of lung cancer are made via radiography.
Recommendations suggest three staging tests before surgery in patients for suspected lung cancer: computed tomography (CT), positron emission tomography (PET), and a biopsy.
According to the study results, 88% of patients did not undergo biopsy, no imaging test was obtained in 22% of patients, and no diagnostic procedure was done before surgery in 27% of patients.
The researchers conclude that delays in final treatment and missed diagnostic tests can hinder outcomes for patients with lung cancer.
Their results highlight the importance of engaging patients in their care from early on to determine the best tests that will lead to an optimal treatment course for that patient.
A team sought to identify the impact of factors associated with care delivery on prognosis for patients with lung cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|